Skip to content

Study · Ex vivo tissue · rat · 2004

2 results

Vasoactive intestinal polypeptide phase-advances the rat suprachiasmatic nuclei circadian pacemaker in vitro via protein kinase A and mitogen-activated protein kinase.

Meyer-Spasche A, Piggins HD

Neuroscience letters1 Mar 2004Cited by 38 (Europe PMC)

PMID15026156 (opens in a new tab)DOI10.1016/j.neulet.2003.12.114 (opens in a new tab)PepBankPUB-15026156
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In rat suprachiasmatic nuclei in vitro, VIP phase-advanced the circadian pacemaker.

    In plain wordsIn lab tests on rat brain tissue, VIP shifted the body clock earlier.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicablePhase advance of the SCN circadian pacemaker
    Study

    ratn: not reported in source

    Rat suprachiasmatic nuclei in vitro
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Title
    Vasoactive intestinal polypeptide phase-advances the rat suprachiasmatic nuclei circadian pacemaker in vitro via protein kinase A and mitogen-activated protein kinase.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism

    In rat suprachiasmatic nuclei in vitro, the PKA inhibitor KT5720 and the MAPKK inhibitor U0126 both blocked phase advances evoked by VIP or the VPAC2 agonist Ro 25-1553.

    In plain wordsIn lab tests on rat brain tissue, two enzyme blockers stopped the clock shift caused by VIP or a VPAC2 agonist.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableBlock of VIP-induced phase advance by PKA or MAPKK inhibitors
    Study

    ratn: not reported in source

    Rat suprachiasmatic nuclei in vitro
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Both inhibitors blocked VIP or Ro 25-1553-induced phase advances, indicating that the late-night resetting actions of VIP via the VPAC(2) receptor require PKA and MEK.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.